MNPR: Volatility Compression detected on 4 Sep 2026

MNPR is forming a volatility compression pattern at $118.55, trading 5% below 52-week highs and 306% above 52-week lows. The pattern exhibits near-maximum quality scores: structure at 15/15, breakout at 12/13, and volume at 12/12, yielding an overall 78/98. Support sits at $104.48, resistance at $124.82. RSI at 57.99 indicates neutral momentum, while volume is tracking 1.04x average at 208k shares. The Bollinger Band position of 0.755 confirms price compression near upper extremes.

In April 2026, Monopar presented Phase 3 FoCus trial analyses at the American Academy of Neurology Annual Meeting demonstrating greater neurologic benefit of ALXN1840 versus standard-of-care in Wilson disease patients with neurologic symptoms. The company expects to submit the ALXN1840 New Drug Application in mid-2026, supported by Phase 3 FoCus trial data. As of March 2026, cash and investments stood at $137.5 million, funding operations through December 2027 including regulatory and potential commercial activities for ALXN1840. On August 13, 2026, Barclays reiterated a Buy rating on Monopar with a $125 price target as ALXN-1840 advances in Wilson disease. The stock has surged nearly 2,000% in a year driven by the ALXN-1840 acquisition.

A successful breakout above $124.82 resistance would target $121.87 conservatively, though upside momentum could extend higher given the bullish regime context (59 score) and sector tailwinds (57 regime score). Volume confirmation would require sustaining current relative volume near 1.0x—typical for biotech moves—without a spike that would signal capitulation. The invalidation level sits at $104.48 support; a close below that would signal pattern failure. With a win probability of 66.33%, historical analogs suggest this compression favors directional breakout over mean reversion.

Q1 2026 net loss widened to $3.9 million per share from $2.6 million year-over-year, with R&D expenses rising 112% to $3.5 million, reflecting peak burn phase ahead of NDA submission. The MNPR-101 radiopharmaceutical pipeline is in early clinical stages with limited data and no clear timeline for further results, creating concentration risk on ALXN1840's regulatory pathway. Company insiders have collectively sold $2.3 million more than purchased over the last 12 months, suggesting reduced conviction at elevated valuations. The NDA submission timeline remains fluid—any delay or insufficient FDA feedback could trigger a sharp reversal below support. Biotech volatility (ATR 7.16, 6.04% of price) remains elevated despite beta of 0.67.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.